Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaphorum podcast

Market Access

Episode 35 of the pharmaphorum podcast hears from Michael Smyth about Galapagos UK and joining the company as medical director just as COVID-19 hit. With RNA-based technology hitting the headlines in recent months due to its use in Covid vaccines, he also discusses the version of it that Galapagos uses and how it can produce compounds that might alter the course of a disease. Michael also tells the podcast about some of the challenges that pharma can face in launching innovative therapies in the UK and the types of evidence that HTA bodies like NICE need for RNA-based drugs. You can listen to episode 35 of the pharmaphorum podcast in the player below, download the episode to your computer or find it – and subscribe to the rest of the series in iTunes, Spotify, acast, Stitcher and Podbean.